MARKET

CMPX

CMPX

Compass Therapeutics Inc
NASDAQ
2.650
+0.010
+0.38%
Pre Market: 2.700 +0.05 +1.89% 04:16 07/09 EDT
OPEN
2.650
PREV CLOSE
2.640
HIGH
2.700
LOW
2.620
VOLUME
755
TURNOVER
0
52 WEEK HIGH
4.080
52 WEEK LOW
0.8180
MARKET CAP
366.45M
P/E (TTM)
-6.6151
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CMPX last week (0630-0704)?
Weekly Report · 2d ago
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Drive Buy Rating
TipRanks · 07/02 09:07
Compass Therapeutics Price Target Announced at $9.00/Share by Raymond James
Dow Jones · 07/01 15:51
Raymond James Reinstates Outperform on Compass Therapeutics, Announces $9 Price Target
Benzinga · 07/01 15:42
Promising Outlook for Compass Therapeutics: Buy Rating Backed by Tovecimig’s Potential and Strategic Positioning
TipRanks · 07/01 10:55
Compass Therapeutics resumed with an Outperform at Raymond James
TipRanks · 07/01 10:50
Weekly Report: what happened at CMPX last week (0623-0627)?
Weekly Report · 06/30 10:47
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
TipRanks · 06/26 16:26
More
About CMPX
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.

Webull offers Compass Therapeutics Inc. stock information, including NASDAQ: CMPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPX stock methods without spending real money on the virtual paper trading platform.